PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...

The San Francisco 49ers may not have any opportunity to play their way into the playoffs in their Week 18 matchup against the ...

PF-07826390 is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer and renal cell carcinoma. It acts by targeting leukocyte immunoglobulin like ...

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices ...